Gapping up
In reaction to strong earnings/guidance: N/A.
M&A news:
In reaction to strong earnings/guidance: N/A.
M&A news:
- SIEN +3% (to acquire Miramar Labs for an aggregate transaction value of $20 mln in upfront cash plus contractual rights for potential contingent payments)
Other news:
- TROV +37% (enters into an agreement with AstraZeneca (AZN) to provide Trovera urine ctDNA biomarker test and services)
- ABIL +16.6% (continued volatility in pre-mkt)
- FCSC +16% (FDA has granted Rare Pediatric Disease Designation to FCX-013)
- QIWI +12.7% (still checking)
- APOP +9.1% (receives a formal notice of allowance for patent application No. 14/383,288 covering a key composition of matter and method of use)
- XBIT +7.5% (modestly rebounding following Friday's declines)
- GNMK +7.5% (receives 510(k) market clearance from the FDA for both its ePlex instrument and Respiratory Pathogen Panel)
- EIGR +5.8% (announces positive data from the Phase 2 multiple-ascending dose study evaluating subcutaneous exendin 9-39)
- MZOR +4.4% (modestly rebounding from last week's decline)
- GTXI +4.2% (presents prelim data from its Phase 2 clinical trial of enobosarm)
- GE +3.6% (names John Flannery Chairman and CEO; Jeff Immelt to retire at the end of the year)
- CNIT +2.8% (signs $1 mln cloud-based ad terminal contract for Anhui Province)
- HLT +2.4% (will replace Yahoo! in the S&P 500)
- TSRO +2.3% (provides update regarding the status of a clinical trial of niraparib sponsored by Janssen Biotech (JNJ); temporary enrollment hold is not due to any safety concerns)
- NVO +1.7% (presents study suggesting switching to Tresiba provides significant reductions in blood glucose and lower rates of hypoglycaemia)
Analyst comments:
- VOD +1.3% (upgraded to Buy from Hold at Argus)